Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297009 | 0.81 | KDM4E (0.47) | MEN1KMT2AKDM4E | |
| SCHEMBL4294380 | 0.80 | S1PR4 (0.38) | S1PR4PTGDR2HCRTR1HCRTR2MEN1 | |
| SCHEMBL4287418 | 0.79 | KDM4E (0.47) | MEN1KMT2AGAALMNAKDM4E | |
| SCHEMBL4284003 | 0.79 | HCRTR1 (0.41) | HCRTR1HCRTR2GAAKDM4E | |
| SCHEMBL4285755 | 0.79 | KDM4E (0.51) | MEN1KMT2ALMNAKDM4E | |
| SCHEMBL4288941 | 0.79 | KMT2A (0.35) | MEN1KMT2AFNTAFNTBKDM4E | |
| SCHEMBL4294041 | 0.78 | HCRTR1 (0.40) | HCRTR1HCRTR2MEN1KMT2AKDM4E | |
| SCHEMBL4288262 | 0.78 | FFAR1 (0.39) | PTGDR2HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL4284656 | 0.78 | FFAR1 (0.42) | HCRTR1HCRTR2MEN1KMT2AKDM4E | |
| SCHEMBL4287638 | 0.78 | LMNA (0.50) | MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | S1PR4 2749/4885PTGDR2 1872/4885HCRTR1 3147/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | S1PR4 2749/4885PTGDR2 1872/4885HCRTR1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.